Passage Bio, Inc. (PASG)

NCM – Real vaqt narxi. Valyuta: USD

5.03

+0.63 (14.32%)

Yopilishda: May 12, 2026, 4:00 PM EDT

4.80

-0.23 (-4.57%)

Bozor oldidan: May 13, 2026, 7:28 AM EDT

20.04.2026

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels

03.03.2026

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim safety and biomarker data from upliFT-D and obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026 Advancing differentiated preclinical program for Huntington's with clinical candidate selection expected in 2H 2026 Cash runway through 1Q 2027 PHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights. “We are proud of the progress made in 2025 as we meaningfully advanced our PBFT02 clinical program for the treatment of genetic forms of frontotemporal dementia,” said Will Chou, M.D.

19.02.2026

Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences: Oppenheimer 36 th Annual Healthcare Life Sciences Conference Format: Management will participate in a presentation and investor meetingsDate: Thursday, February 26, 2026Presentation Time: 8:40 a.m. ETLocation: Virtual TD Cowen 46 th Annual Health Care Conference Format: Management will participate in a presentation and investor meetingsDate: Wednesday, March 4, 2026Presentation Time: 1:50 p.m.

10.11.2025

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish comparability of a high-productivity, suspension-based PBFT02 manufacturing process On track to obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026 Cash runway into 1Q 2027 PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent business highlights. “We are pleased to report that we have opened enrollment in our third FTD-GRN and first FTD-C9orf72 patient cohorts in our ongoing upliFT-D clinical trial of PBFT02.

05.11.2025

Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in a fireside chat during the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 9:30 a.m. ET in Boston, MA.

12.08.2025

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Submitted amended upliFT-D study protocol to global trial sites and health authorities Cash runway into 1Q 2027 PHILADELPHIA, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2025, and provided recent business highlights. “We continue to be encouraged by the emerging data from our upliFT-D clinical trial, which underscore the potential of PBFT02 to offer differentiated therapy for the FTD-GRN patient community.

Videolar

No Data

There is no data to display

Press-relizlar

20.04.2026

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels

03.03.2026

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

10.11.2025

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

12.08.2025

Passage Bio, Inc. (PASG)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Passage Bio, Inc. (PASG)

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Passage Bio to Participate in Upcoming Investor Conferences

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Videolar

No Data

Press-relizlar

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Passage Bio to Participate in Upcoming Investor Conferences

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Videolar

No Data

Press-relizlar

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Search stocks

Passage Bio, Inc. (PASG)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Passage Bio, Inc. (PASG)

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Passage Bio to Participate in Upcoming Investor Conferences

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Videolar

No Data

Press-relizlar

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Passage Bio to Participate in Upcoming Investor Conferences

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Videolar

No Data

Press-relizlar

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights